These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Kamat PP; Gupta S; Ensor JE; Murthy R; Ahrar K; Madoff DC; Wallace MJ; Hicks ME Cardiovasc Intervent Radiol; 2008; 31(2):299-307. PubMed ID: 17922160 [TBL] [Abstract][Full Text] [Related]
8. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421 [TBL] [Abstract][Full Text] [Related]
9. Treatment of melanoma metastases confined to the liver and future perspectives. Vahrmeijer AL; van de Velde CJ; Hartgrink HH; Tollenaar RA Dig Surg; 2008; 25(6):467-72. PubMed ID: 19212119 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in 1,521 melanoma patients with distant metastases. Barth A; Wanek LA; Morton DL J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
13. Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors. de Ridder J; van Walsum M; Verhoef C; Nagtegaal I; de Wilt J; Melanoma Res; 2013 Feb; 23(1):27-32. PubMed ID: 23164992 [TBL] [Abstract][Full Text] [Related]
14. Hepatic arterial chemoembolization for management of metastatic melanoma. Sharma KV; Gould JE; Harbour JW; Linette GP; Pilgram TK; Dayani PN; Brown DB AJR Am J Roentgenol; 2008 Jan; 190(1):99-104. PubMed ID: 18094299 [TBL] [Abstract][Full Text] [Related]
15. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea. Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562 [TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Siegel R; Hauschild A; Kettelhack C; Kähler KC; Bembenek A; Schlag PM Eur J Surg Oncol; 2007 Jun; 33(5):627-32. PubMed ID: 17196362 [TBL] [Abstract][Full Text] [Related]
17. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765 [TBL] [Abstract][Full Text] [Related]
18. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785 [TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Schuster R; Lindner M; Wacker F; Krössin M; Bechrakis N; Foerster MH; Thiel E; Keilholz U; Schmittel A Melanoma Res; 2010 Jun; 20(3):191-6. PubMed ID: 20335820 [TBL] [Abstract][Full Text] [Related]
20. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104). Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]